The best Medicare plans for cancer patients are a Medigap Plan G from AARP and a Medicare Part D plan from Wellcare. Alternatively, if your cancer diagnosis means you can't qualify for Medigap, choose a Medicare Advantage plan from Aetna. In both cases ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news release.

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Cancer treatment costs about $150,000 per patient.  In 2015, spending for cancer treatment and care in the United States was estimated at $183 billion | Cancer

Researchers utilized the comprehensive score for financial toxicity tool to measure self-reported financial distress among 1500-plus patients with cancer or autoimmune diseases receiving charitable copay assistance foundation support.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.